samedan logo
 
 
spacer
home > events calendar
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR
   
  
EVENTS FOR 2008
   
 
EVENTS FOR ICT
 
     

Exploratory Clinical Development World Americas 2008

23-25 September 2008
Philadelphia Marriott Downtown, 1201 Market Street, Philadelphia, Pennsylvania, 19107 USA

Following on from the huge success of the Exploratory Clinical Development World Europe, the Americas congress will give you a critical insight into the latest strategies on how the industry is addressing and elevating the current challenges in early clinical development. More>>

 
 

Clinical Trials Logistics

21-22 May 2008
Crown Plaza – The City Hotel, London, UK

The total R&D investment of bringing a new product to market has been estimated to be close to £400 million. All new products need go through clinical trials and every stage of a clinical trial involves logistics. The effective transport of clinical trials to investigator sites, and patient samples back to central laboratories are critical if a product is to be launched on time and within budget. Delays are expensive and even a few days could potentially cost millions of pounds. The pressure of bringing drugs to market quickly and cheaply, has lead to many clinical trials now being carried out in Asia and Eastern Europe. Each country has its own guidelines which can be highly regulated, so it is crucial to understand the complexities of shipping trial materials to a variety of destinations. More>>

 
 
spacer

Industry Events

EuroBiopartnering 2008

7-9 October 2008, Paris, France

EuroBiOpartnering 2008 gives you the unique opportunity to meet the relevant decision makers and opinion leaders from the international biotech community and offers you 3 days of partnering opportunities including one-to-one meetings, company presentations and further networking activities… Learn more  
More info >>

News and Press Releases

PFIZER PRESENTS OVERALL SURVIVAL DATA FOR SUTENT™ VERSUS INTERFERON-ALFA

Chicago, 31 May 2008- Results from a landmark study have shown that sunitinib (SUTENT™) has demonstrated overall survival greater than two years in patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer.  This is the first time overall survival data representing more than two years has been achieved in the first line setting of mRCC, which is clinically meaningful and reflective of major advances in the treatment of kidney cancer. 
More info >>

 
©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement